<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00100126</url>
  </required_header>
  <id_info>
    <org_study_id>231.301</org_study_id>
    <nct_id>NCT00100126</nct_id>
  </id_info>
  <brief_title>APC-231 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) in Pediatric Patients With Strep Throat</brief_title>
  <official_title>A Phase III, Investigator Blind, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of APC-231 Sprinkle QD for 7 Days vs Penicillin VK 10 mg/kg QID for 10 Days in Pediatric Patients With Streptococcus Pyogenes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advancis Pharmaceutical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advancis Pharmaceutical Corporation</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of APC-231 QD for 7 days in&#xD;
      the bacteriological outcome at the Test of Cure Visit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date>June 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacteriological outcome at Test of Cure Visit</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacteriological outcome at Late Post Therapy Visit</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcomes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment>500</enrollment>
  <condition>Pharyngitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin Pulsatile Release Multiparticluate Sprinkle</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Give informed consent, assent, and documentation of patient authorization for disclosure of&#xD;
        study results.&#xD;
&#xD;
        Since all patients are below the legal age of consent, assent from the patient must be&#xD;
        obtained (as applicable following state regulations) and written informed consent obtained&#xD;
        from the parent or legal guardian.&#xD;
&#xD;
          -  Age &gt; = 6 months -12 years.&#xD;
&#xD;
          -  A clinical diagnosis of acute tonsillitis and/or pharyngitis defined as having the&#xD;
             clinical signs and symptoms compatible with tonsillitis and/or pharyngitis, including&#xD;
             sore throat or difficulty feeding or swallowing or irritability that suggests the&#xD;
             presence of a sore throat with at least one of the following:&#xD;
&#xD;
               -  Tonsillar or pharyngeal exudate&#xD;
&#xD;
               -  Tender cervical lymph nodes&#xD;
&#xD;
               -  Fever or history of fever treated with antipyretics&#xD;
&#xD;
               -  Odynophagia&#xD;
&#xD;
               -  Uvular edema&#xD;
&#xD;
               -  Pharyngeal Erythema of moderate or greater intensity&#xD;
&#xD;
               -  Elevated white blood cell (WBC) &gt;12,000/mm3 or 10% bands&#xD;
&#xD;
               -  Red tongue and prominent papillae (Strawberry tongue)&#xD;
&#xD;
          -  A positive rapid screening test for S. pyogenes (enzyme immunoassay; SiGNIFY™ Strep A&#xD;
             Test).&#xD;
&#xD;
          -  Patient is an appropriate candidate for oral antibiotic therapy and can swallow the&#xD;
             study dosage forms.&#xD;
&#xD;
          -  Females must be non-lactating and:&#xD;
&#xD;
               -  If of childbearing potential and sexually active, the patient must have a&#xD;
                  negative prestudy urine pregnancy test and be utilizing acceptable birth control&#xD;
                  methods throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic or recurrent (two weeks duration two times per year) odynophagia or enlarged&#xD;
             tonsils secondary to viral or proven bacterial etiology.&#xD;
&#xD;
               -  The need for hospitalization or I.V. antimicrobial therapy.&#xD;
&#xD;
               -  Pharyngitis known or suspected to be due to a pathogen resistant to beta-lactam&#xD;
                  antimicrobials.&#xD;
&#xD;
               -  Patients who are known carriers of S. pyogenes.&#xD;
&#xD;
               -  Previous allergy, serious adverse reaction to, or intolerance to, penicillin or&#xD;
                  any other member of the beta-lactam class of antimicrobials.&#xD;
&#xD;
               -  Any serious illness or concomitant condition that the investigator judges would&#xD;
                  preclude the study evaluations or make it unlikely that the course of study&#xD;
                  therapy and follow-up could be completed. This would also include:&#xD;
&#xD;
          -  Any rapidly progressive underlying disease with a shortened life expectancy.&#xD;
&#xD;
          -  The inability to swallow the study dosage form.&#xD;
&#xD;
          -  Unable to understand the requirements of the study.&#xD;
&#xD;
          -  Neutropenia (&lt;1000 PMNs/mm3) or other known immunocompromised state.&#xD;
&#xD;
          -  Hard chills or rigors.&#xD;
&#xD;
               -  Seizure disorder or lowered seizure threshold. This does not exclude children&#xD;
                  with previous febrile seizures.&#xD;
&#xD;
               -  Psychiatric condition requiring use of major tranquilizers.&#xD;
&#xD;
               -  Pregnancy or nursing.&#xD;
&#xD;
               -  Expectation that additional effective systemic antibacterials would be required&#xD;
                  for any condition during the duration of the study.&#xD;
&#xD;
               -  Current drug or alcohol abuse.&#xD;
&#xD;
               -  Receipt of any experimental drug or medical device within the previous 30 days&#xD;
                  (or are scheduled to receive any other experimental procedures during the study&#xD;
                  period).&#xD;
&#xD;
               -  Previous treatment under this protocol.&#xD;
&#xD;
               -  Systemic antimicrobial therapy with benzathine penicillin within 30 days or&#xD;
                  azithromycin within 14 days.&#xD;
&#xD;
               -  Hospitalization within the month prior to study admission, during which&#xD;
                  antibacterial therapy was administered.&#xD;
&#xD;
               -  The presence of clinically significant hematologic conditions or cardiac valvular&#xD;
                  disease.&#xD;
&#xD;
               -  History of cardiovascular disease, renal disease, or neurological disease&#xD;
                  secondary to previous infection with S. pyogenes.&#xD;
&#xD;
               -  Probenecid treatment or systemic steroids during the duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Clausen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Advancis Pharmaceutical Corp</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Neuroscience Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2005</verification_date>
  <study_first_submitted>December 23, 2004</study_first_submitted>
  <study_first_submitted_qc>December 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2004</study_first_posted>
  <last_update_submitted>October 23, 2006</last_update_submitted>
  <last_update_submitted_qc>October 23, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2006</last_update_posted>
  <keyword>Pharyngitis</keyword>
  <keyword>Strep throat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharyngitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

